ArticleThorax2001
Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.
Article in Thorax, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Patterns of inflammation and the use of reversibility testing in smokers with airway complaints.BMC pulmonary medicine · 2006Trial
- Genetic resilience to chronic obstructive pulmonary disease is a clinically distinct subtype in individuals with cigarette smoke exposure.Respiratory research · 2025Article
- Association of neutrophil-to-lymphocyte ratio and CRP with spirometry in COPD patients in North India.Journal of family medicine and primary care · 2025Article
- Diagnostic Value of Galectin-3 in Exacerbations of Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2024Article
- Haematological and Inflammatory Biomarkers Among Stable COPD and Acute Exacerbations of COPD Patients.Sultan Qaboos University medical journal · 2023Article
- Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.Annals of the American Thoracic Society · 2021Article
- Inference of Cellular Immune Environments in Sputum and Peripheral Blood Associated with Acute Exacerbations of COPD.Cellular and molecular bioengineering · 2019Article
- The Use of Serum Procalcitonin as a Diagnostic and Prognostic Biomarker in Chronic Obstructive Pulmonary Disease Exacerbations: A Literature Review Update.Journal of clinical medicine research · 2018Review
- Role of accelerated aging in limb muscle wasting of patients with COPD.International journal of chronic obstructive pulmonary disease · 2018Article
- Serum levels of IGFBP7 are elevated during acute exacerbation in COPD patients.International journal of chronic obstructive pulmonary disease · 2017Article
- The Importance of Neutrophil-to-Lymphocyte Ratio in Chronic Obstructive Pulmonary Disease.Turkish thoracic journal · 2016Article
- The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.Journal of clinical and diagnostic research : JCDR · 2015Article
- Chronic obstructive pulmonary disease and the metabolic syndrome: Consequences of a dual threat.Indian journal of endocrinology and metabolism · 2014Review
- Pulmonary rehabilitation: the reference therapy for undernourished patients with chronic obstructive pulmonary disease.BioMed research international · 2014Review
- Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2013Article
- Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study.PloS one · 2013Observational
- Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD.Journal of inflammation (London, England) · 2012Article
- A unique protein profile of peripheral neutrophils from COPD patients does not reflect cytokine-induced protein profiles of neutrophils in vitro.BMC pulmonary medicine · 2011Article
- Systemic inflammation in COPD in relation to smoking status.Multidisciplinary respiratory medicine · 2011Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to test the hypothesis that the chronic inflammatory process present in chronic obstructive pulmonary disease (COPD) is due to a defective endogenous anti-inflammatory mechanism.
methodsSystemic levels of the anti-inflammatory mediators soluble interleukin 1 receptor II (sIL-1RII), soluble tumour necrosis factor receptor p55 (sTNF-R55) and sTNF-R75, and of C reactive protein (CRP) and lipopolysaccharide binding protein (LBP) were analysed in 55 patients with stable COPD (median forced expiratory volume in one second (FEV(1)) 34% predicted (range 15-78)) and compared with levels in 23 control subjects. In addition, changes in these mediators were studied in 13 patients with COPD (median FEV(1) 34% predicted (range 19-51)) during the first 7 days in hospital with an exacerbation of the disease.
resultsPatients with stable COPD were characterised by a systemic inflammatory process indicated by an increased leucocyte count (7.2 (4.7-16.4) v 4.8 (3.5-8.3) x 10(9)/l), raised levels of CRP (11.8 (1.1-75.0) v 4.1 (0.6-75.0) microg/ml) and LBP (45.6 (8.1-200.0) v 27.9 (14.1-71.5) microg/ml), and moderate increases in both sTNF-Rs. In contrast, the sIL-1RII level did not differ between patients and controls (4.53 (2.09-7.60) v 4.63 (3.80-5.93) ng/ml). During treatment of disease exacerbations, systemic levels of both CRP (at day 3) and LBP (at day 7) were significantly reduced compared with day 1, whereas sIL-1RII levels increased.
conclusionsThese data suggest an imbalance in systemic levels of pro- and anti-inflammatory mediators in patients with stable COPD. The increase in the anti-inflammatory mediator sIL-1RII during treatment of exacerbations may contribute to the clinical improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.